[
    {
        "id": "osp-12595",
        "type": "article-journal",
        "title": "Comparison between Ologen implant and different concentrations of Mitomycin C as an adjuvant to trabeculectomy surgery",
        "author": [
            {
                "family": "Eldaly",
                "given": "Zeiad H"
            },
            {
                "family": "Maasoud",
                "given": "Ali A"
            },
            {
                "family": "Saad",
                "given": "Mohamed S"
            },
            {
                "family": "Mohamed",
                "given": "Abdelsalam A"
            }
        ],
        "URL": "https://omanscience.com/en/articles/comparison-between-ologen-implant-and-different-concentrations-of-mitomycin-c-as-an-adjuvant-to-trabeculectomy-surgery",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2017
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "10",
        "issue": "3",
        "page": "184-192",
        "DOI": "10.4103/ojo.ojo_199_2016",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "Context: Trabeculectomy is the most common surgical procedure for treatment of glaucoma. To improve success rates, adjuvants were utilized as Mitomycin C (MMC) and Ologen implant.\n\nAims: This study aims to establish efficacy and safety of Ologen implant versus MMC in trabeculectomy.\n\nSetting and design: A prospective, comparative clinical study was conducted at the Department of Ophthalmology, Assiut University, between December 2014 and April 2016.\n\nSubjects and methods: Patients with primary open-angle glaucoma (OAG), primary narrow-angle glaucoma and secondary OAG were assigned equally to trabeculectomy with Ologen, 0.4 mg/mL or 0.2 mg/mL MMC. The study outcome measures were reduction in intra-ocular pressure (IOP), success rates, survival analysis, and rate of complications.\n\nStatistical analysis used: SPSS software Version 17.0 (SPSS, Inc., IL, USA) was utilized.\n\nResults: Thirty eyes were included in the study. Mean baseline IOP in Ologen, MMC 0.4 and MMC 0.2 groups were 27.43 ± 2.97, 28.4 ± 3.24, and 27.56 ± 2.69 mmHg, respectively. At week 24 follow-up, mean IOP in Ologen, MMC 0.4 and MMC 0.2 groups were 18.55 ± 3.18, 16.2 ± 3.22, and 16.93 ± 3.04 mmHg, respectively. No significant inter-group difference was noticed at any visits. Complete success was achieved in 10%, 40%, and 30%, whereas incomplete success in 70%, 50%, and 60%, respectively in Ologen, MMC 0.4 and MMC 0.2 groups. No treatment group difference was reported by Kaplan-Meier analysis. Shallow anterior chamber occurred more in Ologen and MMC 0.4 groups. A single case of serous choroidal effusion had occurred in MMC 0.4 group.\n\nConclusion: Ologen implant is a promising alternative to MMC for improving the success rate of trabeculectomy."
    }
]